FREQUENCY THERAPEUTICS, INC. (FREQ): Price and Financial Metrics


FREQUENCY THERAPEUTICS, INC. (FREQ): $1.79

-0.03 (-1.65%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add FREQ to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

FREQ POWR Grades

  • FREQ scores best on the Value dimension, with a Value rank ahead of 59.88% of US stocks.
  • FREQ's strongest trending metric is Stability; it's been moving down over the last 179 days.
  • FREQ's current lowest rank is in the Stability metric (where it is better than 3.27% of US stocks).

FREQ Stock Summary

  • FREQUENCY THERAPEUTICS INC's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than only 11.74% of US listed stocks.
  • Revenue growth over the past 12 months for FREQUENCY THERAPEUTICS INC comes in at -72.6%, a number that bests only 1.72% of the US stocks we're tracking.
  • The volatility of FREQUENCY THERAPEUTICS INC's share price is greater than that of 95.7% US stocks with at least 200 days of trading history.
  • If you're looking for stocks that are quantitatively similar to FREQUENCY THERAPEUTICS INC, a group of peers worth examining would be BCAB, AKTS, EDIT, BLUE, and RETA.
  • Visit FREQ's SEC page to see the company's official filings. To visit the company's web site, go to www.frequencytx.com.

FREQ Valuation Summary

  • FREQ's price/earnings ratio is -5; this is 113.7% lower than that of the median Healthcare stock.
  • FREQ's EV/EBIT ratio has moved up 16.9 over the prior 23 months.
  • FREQ's price/sales ratio has moved NA NA over the prior 23 months.

Below are key valuation metrics over time for FREQ.

Stock Date P/S P/B P/E EV/EBIT
FREQ 2021-08-31 7.5 1.6 -5.0 -3.3
FREQ 2021-08-30 7.6 1.6 -5.0 -3.3
FREQ 2021-08-27 7.7 1.6 -5.1 -3.4
FREQ 2021-08-26 7.6 1.6 -5.0 -3.3
FREQ 2021-08-25 7.6 1.6 -5.0 -3.3
FREQ 2021-08-24 7.5 1.6 -5.0 -3.3

FREQ's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • FREQ has a Quality Grade of D, ranking ahead of 8.89% of graded US stocks.
  • FREQ's asset turnover comes in at 0.147 -- ranking 225th of 682 Pharmaceutical Products stocks.
  • 500 - Internal server error

The table below shows FREQ's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.147 1 -0.828
2021-03-31 0.145 1 -1.583
2020-12-31 0.161 1 4.957
2020-09-30 0.145 1 0.830
2020-06-30 0.220 1 0.575
2019-12-31 0.216 1 1.319

FREQ Price Target

For more insight on analysts targets of FREQ, see our FREQ price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $13.50 Average Broker Recommendation 1.7 (Moderate Buy)

FREQ Stock Price Chart Interactive Chart >

Price chart for FREQ

FREQ Price/Volume Stats

Current price $1.79 52-week high $7.88
Prev. close $1.82 52-week low $1.00
Day low $1.79 Volume 68,700
Day high $1.89 Avg. volume 464,137
50-day MA $2.04 Dividend yield N/A
200-day MA $2.57 Market Cap 63.12M

FREQUENCY THERAPEUTICS, INC. (FREQ) Company Bio


Frequency Therapeutics, Inc. is a clinical-stage biotechnology company. It engages in the development of small molecule drugs that activate progenitor cells within the body to restore healthy tissue. T


FREQ Latest News Stream


Event/Time News Detail
Loading, please wait...

FREQ Latest Social Stream


Loading social stream, please wait...

View Full FREQ Social Stream

Latest FREQ News From Around the Web

Below are the latest news stories about FREQUENCY THERAPEUTICS INC that investors may wish to consider to help them evaluate FREQ as an investment opportunity.

Frequency Therapeutics to Participate in September Investor and Medical Conferences

LEXINGTON, Mass., August 30, 2022--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person’s innate potential to restore function, today announced that members of its management team will participate in investor and medical conferences later this month.

Yahoo | August 30, 2022

Frequency Therapeutics Provides Business Updates and Second Quarter 2022 Financial Results

LEXINGTON, Mass., August 09, 2022--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person’s innate potential to restore function, today announced business updates and financial results for the second quarter ended June 30, 2022.

Yahoo | August 9, 2022

Frequency Therapeutics (NASDAQ:FREQ) one-year losses have grown faster than shareholder returns have fallen, but the stock jumps 41% this past week

Frequency Therapeutics, Inc. ( NASDAQ:FREQ ) shareholders will doubtless be very grateful to see the share price up 41...

Yahoo | June 24, 2022

Frequency Therapeutics, Inc. (FREQ) Upgraded to Buy: What Does It Mean for the Stock?

Frequency Therapeutics, Inc. (FREQ) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Yahoo | May 25, 2022

Frequency Therapeutics to Participate in 2022 H.C. Wainwright Global Investment Conference

LEXINGTON, Mass., May 18, 2022--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person’s innate regenerative potential to restore function, today announced that Chief Scientific Officer Dr. Christopher Loose will present at the upcoming H.C. Wainwright Global Investment Conference.

Yahoo | May 18, 2022

Read More 'FREQ' Stories Here

FREQ Price Returns

1-mo -10.50%
3-mo N/A
6-mo -4.79%
1-year -74.65%
3-year -86.93%
5-year N/A
YTD -65.11%
2021 -85.45%
2020 101.14%
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.5322 seconds.